Demographic and disease characteristics of the patients at baseline. Kruskal-Wallis nonparametric test was used for continuous variables and the chi-squared test for categorical variables.
| Characteristic | Adalimumab, n = 324, F: 273, M: 51 | Etanercept, n = 311, F: 268, M: 43 | Infliximab, n = 218, F: 172, M: 46 | ||||
|---|---|---|---|---|---|---|---|
| Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | p | |
| Age, yrs | 54.5 (12) | 55.4 (19) | 53.5 (14) | 54.4 (19) | 51.9 (13) | 52.5 (19) | 0.06 |
| Latency, mo | 9.6 (9.0) | 7.7 (12) | 10.0 (8.6) | 7.9 (11) | 8.8 (7.8) | 6.8 (12) | 0.19 |
| Disease duration, yrs | 11.5 (8.8) | 9.9 (11) | 10.7 (8.6) | 8.7 (10) | 9.9 (7.7) | 8.3 (12) | 0.17 |
| VAS pain, 0–100 | 66.8 (19) | 70 (24) | 70.7 (22) | 71 (38) | 67.1 (24) | 70 (35) | 0.23 |
| ESR, mm/h | 35.7 (22) | 30 (27) | 40.3 (22) | 38 (33) | 40.2 (24) | 35 (31) | 0.06 |
| RF, % | 68 | 70 | 76 | 0.08 | |||
| HAQ | 1.28 (0.5) | 1.2 (0.7) | 1.6 (0.7) | 1.6 (1.0) | 1.5 (0.6) | 1.4 (1.0) | 0.03 |
| DAS28 | 5.37 (1.5) | 5.65 (1.8) | 5.71 (1.5) | 5.98 (1.8) | 5.6 (1.4) | 5.8 (1.4) | 0.04 |
| Glucocorticoid, baseline, % | 29 | 44 | 30 | 0.06 | |||
| DMARD before, % | 97 | 99 | 96 | 0.19 | |||
| DMARD baseline, % | 25 | 31 | 44 | 0.01 | |||
| MTX | 78 | 78 | 81 | ||||
| HCQ | 11 | 11 | 7 | ||||
| Leflunomide | 8 | 8 | 5 | ||||
| Sulfasalazine | 1 | 1 | 4 | ||||
| Cyclosporine | 1 | 4 | 1 | ||||
| Comorbidities, % | 33 | 46 | 21 | 0.01 | |||
VAS: visual analog scale; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; HAQ: health assessment questionnaire; DAS28: Disease Activity Score based on 28 joints; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate; HCQ: hydroxychloroquine; IQR: interquartile range.